微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 20.46% | -6.27% | 1.64% | 138/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 20.13% | 0.37% | -9.54% | 137/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 22.25% | 24.69% | 8.08% | 134/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 20.59% | 5.95% | -5.67% | 136/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 21.83% | 1.81% | 8.84% | 128/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 20.06% | -6.7% | 12.37% | 134/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 17.85% | -19.7% | -8.16% | 135/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 19.43% | -19.98% | -9.36% | 138/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 21.44% | -11.83% | -0.25% | 135/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 21.49% | -8.78% | -3.29% | 137/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 22.23% | 8.33% | -8.48% | 132/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.29% | 1.01% | -0.12% | 133/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 24.32% | -6.15% | 3.2% | 131/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 23.56% | -19.5% | 14.84% | 131/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 20.52% | -34.43% | -14.67% | 130/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 24.04% | -35.71% | -7.2% | 133/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 25.91% | -35.46% | -11.48% | 123/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 29.27% | -31.53% | -6.44% | 118/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 31.29% | -29.3% | -16.34% | 106/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 37.4% | -14.98% | -6.84% | 112/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.15% | -13.64% | -6.1% | 92/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 42.75% | -9.82% | -3.38% | 90/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 44.25% | -2.24% | 0.6% | 77/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 43.99% | 2.96% | -5.38% | 95/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 46.49% | 10.67% | -1.94% | 76/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 47.41% | 13.93% | 4.74% | 80/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 45.27% | 15.3% | 5.95% | 72/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 42.72% | 5.56% | 1.7% | 91/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 42.01% | 1.37% | 0.95% | 72/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 41.62% | 3.64% | 6% | 77/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 39.26% | 1.69% | -3% | 75/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 40.47% | 7.91% | -2.34% | 93/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 41.44% | 5.5% | 3.21% | 68/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 40.15% | 5.9% | 4% | 70/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 38.61% | 0.75% | 2.94% | 74/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.51% | -1.68% | -4.52% | 82/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 39.28% | 3.66% | 3.61% | 60/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 37.92% | 0.49% | -1.05% | 69/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.32% | -1.71% | 0.46% | 53/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 38.15% | 2.66% | 0.66% | 71/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 37.9% | 3.34% | 0.44% | 49/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 37.73% | 2% | -3.22% | 56/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 38.99% | 2% | 4.93% | 43/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |